Cuu Long Pharmaceutical JSC
HHOSE:DCL49,500.00
VND
0.00
(0.00%)
ISIN
VN000000DCL1
Return %
Stock
S&P 500
1Y
59.68
14.20
3Y
118.54
81.12
5Y
36.36
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Minh Hoai Thi Vu
- Full Time Employees
- 878
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Vinh Long Vietnam
- IPO Date
- Sep 17, 2008
- Website
- dcl.com.vn
- Similar Companies
- Business
- Cuu Long Pharmaceutical Joint Stock Company is a Vietnam-based healthcare enterprise engaged in the manufacturing, processing, and commercialization of pharmaceutical medications, empty hard capsules, and medical devices. Founded in 1976 and headquartered in Vinh Long Province, Vietnam, the company operates as a major pharmaceutical subsidiary of F.I.T Group Joint Stock Company. Cuu Long Pharmaceutical conducts its business through three primary operating segments: Pharmaceuticals, Capsule Manufacturing, and Medical Supplies. Its Pharmaceuticals segment develops and produces over 250 prescription and over-the-counter formulations across multiple therapeutic categories, including antibiotics, anti-infectives, analgesics, antipyretics, and anti-inflammatory drugs; cardiovascular, metabolic, and antidiabetic agents; respiratory, antihistamine, and gastrointestinal medications; musculoskeletal and nervous system therapies; and vitamins, minerals, and herbal remedies, supported by raw material sourcing from a dedicated medicinal herb farm in Binh Phuoc Province. The Capsule Manufacturing segment produces hard gelatin and vegetarian empty capsules under the Vicancap brand for domestic and regional pharmaceutical manufacturers. The Medical Supplies segment produces single-use medical consumables and devices under the Benovas and Vikimco brands, including sterile hypodermic syringes, infusion sets, IV administration sets, scalp vein needles, and surgical supplies. The company distributes its portfolio nationwide through hospital tender channels and retail pharmacy networks, while exporting across Southeast Asian markets such as Cambodia, Laos, and Myanmar. In recent developments, Cuu Long Pharmaceutical has executed extensive manufacturing expansions, including the operational launch of its Phase 5 Vicancap capsule facility upgrade to reach an annual production capacity of approximately 9.6 billion capsules. The company is also advancing the development of an EU-GMP compliant pharmaceutical plant with a projected annual capacity of 1.6 billion units, progressing the construction of the Benovas medical device production facility in Vinh Long, and pursuing strategic international partnerships, including collaboration with Canada-based Pharmascience to expand and diversify its specialty drug portfolio following the structural divestment and streamlining of non-core legacy entities.